

PAULA T. DOW
ATTORNEY GENERAL OF NEW JERSEY
Division of Law, 5th Floor
124 Halsey Street
P.O. Box 45029
Newark, New Jersey 07101
Attorney for New Jersey Board of Pharmacy

FILED

NOV 10 2010

BOARD OF PHARMACY

By: Jodi C. Krugman
Deputy Attorney General
Tel: (973) 648-2436

STATE OF NEW JERSEY
DEPARTMENT OF LAW & PUBLIC SAFETY
DIVISION OF CONSUMER AFFAIRS
STATE BOARD OF PHARMACY

IN THE MATTER OF THE APPLICATION OF: :	Administrative Action
:	:
KENNETH RIZZO, R.P.	CONSENT ORDER
License No. RI0201600	OF REINSTATEMENT
:	:
FOR REINSTATEMENT OF LICENSURE :	:
TO PRACTICE PHARMACY IN THE :	:
STATE OF NEW JERSEY :	:

This matter was opened to the New Jersey State Board of Pharmacy (the "Board") upon receipt of respondent Kenneth Rizzo's ("respondent") request for reinstatement of his license to practice pharmacy in this State. Respondent was the subject of a Final Order of Discipline filed on August 3, 2006, which suspended respondent's license for three years.¹

In support of his application, respondent, represented by Angelo Cifaldi, Esq., testified before the Board on May 12, 2010, concerning his conviction and reasons for

¹ Although the Final Order requires the suspension to be concurrent with respondent's license suspension in New York, respondent testified that he voluntarily surrendered his license in New York and has no intention of seeking to reinstate his New York license.

seeking reinstatement. He testified that he overbilled Medicaid in connection with his home infusion business, and as a result of a guilty plea, served six months in prison and made restitution to Medicaid of approximately \$900,000. In addition, beginning on or about April 4, 2006, he is prohibited from participating in Medicaid and Medicare programs for 23 years.

Respondent, being desirous of resolving this matter without the necessity of further formal proceedings, and agreeing to waive any right to same, and the Board having determined that this Order is sufficiently protective of the public health, safety and welfare, and all parties agreeing to the terms of this Order;

**IT IS THEREFORE ON THIS 10th DAY OF NOVEMBER, 2010,
ORDERED AND AGREED THAT:**

1. Respondent's license to practice pharmacy in the State of New Jersey is hereby reinstated subject to the conditions set forth in this Order.
2. Prior to license reinstatement, respondent shall undergo a criminal history record background check and pay all reinstatement fees. If the criminal history background check reveals any information other than that addressed in the Final Order of Discipline, respondent shall provide an explanation of the relevant conduct prior to any reinstatement of his license. Respondent shall also submit proof of 45 credits of continuing education.
3. For a period of two years commencing on the date of reinstatement of his license, respondent shall not act as a preceptor or a pharmacist-in-charge (RPIC) at any

pharmacy and shall not own or have an ownership interest in any pharmacy. Periods of time when respondent is not engaged in the active practice of pharmacy shall not count toward the two years set forth herein.

4. Respondent shall serve a copy of this Order on all employers, licensee supervisors, and/or responsible entities or officials at each and every facility where he plans to practice pharmacy, prior to commencing work as a licensee and shall ensure that each employer and licensee supervisor sends documentation to the Board that he or she has reviewed the complete Order. This provision shall apply until respondent is removed from the OIG debarment list.

5. Respondent shall continue to cease and desist from filling any prescriptions for Medicaid or any other program, consistent with the debarment order from OIG.

6. Respondent shall be subject to an Order of automatic suspension of his license upon the Board's receipt of any information which the Board, in its sole discretion, deems reliable demonstrating that respondent has failed to comply with any of the conditions set forth in this Order, including, but not limited to filling of prescriptions in violation of the OIG debarment. Respondent shall have a right to apply for removal of the automatic suspension on ten (10) days notice to the Board and to the Attorney General.

The Board may hold a hearing on that application before the full Board or before a committee of the Board. In the event a committee hears the application, its action shall be subject to ratification of the full Board at its next scheduled meeting

NEW JERSEY STATE BOARD OF PHARMACY

By: Edward G. McGinley
Edward G. McGinley, R.Ph.
President

I have read the within Order,
understand its terms and agree
to be bound by them. I
consent to entry of the Order
by the Board of Pharmacy.

Kenneth Rizzo, R.P.
Respondent

Consent is given as to form and entry
of this Order

Angelo Cifaldi, Esq.
Counsel for Respondent

The Board may hold a hearing on that application before the full Board or before a committee of the Board. In the event a committee hears the application, its action shall be subject to ratification of the full Board at its next scheduled meeting

NEW JERSEY STATE BOARD OF PHARMACY

By: Edward G. McGinley
Edward G. McGinley, R.Ph.
President

I have read the within Order,
understand its terms and agree
to be bound by them. I
consent to entry of the Order
by the Board of Pharmacy.

Kenneth Rizzo
Kenneth Rizzo, R.P.
Respondent

Consent is given as to form and entry
of this Order

Angelo Cifardi
Angelo Cifardi, Esq.
Counsel for Respondent

Statement of Credit

Ken J. Rizzo,
11 High Ridge Rd
Montvale, NJ 07645-1508

Print



Close Window

With this Statement of Credit *Pharmacist's Letter* Therapeutic Research Center confirms that
Ken J. Rizzo has successfully completed the courses below:

State: New Jersey

Renewal Period: 9/1/2009 - 8/31/2011

Course Title & CE Provider	Date Completed	Contact Hours	Requirements Met
Emerging Developments in Drug Therapy and Implementation into Patient Care May 2010 ACPE#: 0422-0000-10-005-H01-P Knowledge-based CE 61d525d4-28bd-4acb-bcb8-640090009509 (printed previously)	05/16/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care April 2010 ACPE#: 0422-0000-10-004-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/16/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care March 2010 ACPE#: 0422-0000-10-003-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/16/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care May 2008 ACPE#: 422-000-08-005-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/23/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care June 2008 ACPE#: 422-000-08-006-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/23/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care July 2008 ACPE#: 422-000-08-007-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/23/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care August 2008 ACPE#: 422-000-08-008-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/25/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care September 2008 ACPE#: 422-000-08-009-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/25/10	1.00	General CE

Emerging Developments in Drug Therapy and Implementation into Patient Care October 2008 ACPE#: 422-000-08-010-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/25/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care May 2009 ACPE#: 422-000-09-005-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/30/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care July 2009 ACPE#: 422-000-09-007-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/30/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care August 2009 ACPE#: 422-000-09-008-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/31/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care September 2009 ACPE#: 422-000-09-009-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/31/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care October 2009 ACPE#: 0422-0000-09-010-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	05/31/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care November 2009 ACPE#: 0422-0000-09-011-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	06/01/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care December 2009 ACPE#: 0422-0000-09-012-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	06/05/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care January 2010 ACPE#: 0422-0000-10-001-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	06/05/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care February 2010 ACPE#: 0422-0000-10-002-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	06/20/10	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care June 2010 ACPE#: 0422-0000-10-006-H01-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	06/20/10	1.00	General CE

A Guide to Generic Substitution: A Law CE ACPE#: 422-000-09-802-H03-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	06/20/10	1.00	Law CE
The Safe Use of High-Alert Medications in the Community Pharmacy ACPE#: 422-000-09-804-H05-P Knowledge-based CE 61d525d4-650a-4834-a674-507c1e4c0aee (printed previously)	06/20/10	1.00	General CE
PL CE LIVE August Forum 2010 ACPE#: 0422-0000-10-508-L01-P Knowledge-based CE 4be223b4-6929-4b97-a728-2fb12b8ddf35 (printed previously)	08/06/10	1.00	Live CE
PL CE LIVE July Forum 2010 ACPE#: 0422-0000-10-507-L01-P Knowledge-based CE 4be223b4-6929-4b97-a728-2fb12b8ddf35 (printed previously)	08/12/10	1.00	Live CE
PL CE LIVE June Forum 2010 ACPE#: 0422-0000-10-506-L01-P Knowledge-based CE 4be223b4-6929-4b97-a728-2fb12b8ddf35 (printed previously)	07/29/10	1.00	Live CE
Medication Safety: Strategies for Preventing Medication Errors ACPE#: 422-000-09-515-L05-P Knowledge-based CE 4be223b4-6929-4b97-a728-2fb12b8ddf35 (printed previously)	09/18/10	2.00	Live CE
Pharmacy Law Update ACPE#: 422-000-07-212-H03-P Knowledge-based CE 4be223b4-6929-4b97-a728-2fb12b8ddf35 (printed previously)	10/18/10	1.00	Law CE

and is awarded 27.00 total Contact Hours



Tony R. Martin

Tony R. Martin, Pharm.D., MBA October 25, 2010

These courses are sponsored by
Pharmacist's Letter, 3120 W. March Lane, PO Box 8190, Stockton, CA 95208
TEL: (209) 472-2240 FAX: (209) 472-2249

Print

Close Window

Statement of Credit

Ken J. Rizzo
11 High Ridge Rd
Montvale, NJ 07645-1508

Print



Close Window

With this Statement of Credit *Pharmacist's Letter* Therapeutic Research Center confirms that
Ken J. Rizzo has successfully completed the courses below:

State: New Jersey

Renewal Period: 9/1/2007 - 8/31/2009

c19992e8-aff-46aa-9b95-e198ea186ec9

Course Title & CE Provider	Date Completed	Contact Hours	Requirements Met
HIV/AIDS: Drug Therapy Update ACPE#: 422-000-07-201-H02-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	08/18/08	3.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care August 2008 ACPE#: 422-000-06-008-H01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	08/26/08	1.00	General CE
PL CE LIVE August Forum 2008 ACPE#: 422-000-08-508-L01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	08/26/08	1.00	Live CE
PL CE LIVE September Forum 2008 ACPE#: 422-000-08-509-L01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	09/04/08	1.00	Live CE
PL CE LIVE October Forum 2008 ACPE#: 422-000-08-510-L01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	10/09/08	1.00	Live CE
Emerging Developments in Drug Therapy and Implementation into Patient Care December 2008 ACPE#: 422-000-08-012-H01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	11/25/08	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care November 2008 ACPE#: 422-000-08-011-H01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	11/25/08	1.00	General CE
PL CE LIVE November Forum 2008 ACPE#: 422-000-08-511-L01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	12/04/08	1.00	Live CE
PL CE LIVE January Forum 2009 ACPE#: 422-000-09-501-L01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	01/06/09	1.00	Live CE

Emerging Developments in Drug Therapy and Implementation into Patient Care January 2009 ACPE#: 422-000-09-001-H01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	01/07/09	1.00	General CE
<i>PL CE LIVE</i> December Forum 2008 ACPE#: 422-000-08-512-L01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	01/15/09	1.00	Live CE
<i>PL CE LIVE</i> February Forum 2009 ACPE#: 422-000-09-502-L01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	02/03/09	1.00	Live CE
Emerging Developments in Drug Therapy and Implementation into Patient Care April 2009 ACPE#: 422-000-09-004-H01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	03/29/09	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care March 2009 ACPE#: 422-000-09-003-H01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	03/29/09	1.00	General CE
Emerging Developments in Drug Therapy and Implementation into Patient Care February 2009 ACPE#: 422-000-09-002-H01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	03/29/09	1.00	General CE
<i>Pharmacist's Letter / Prescriber's Letter</i> on Cholesterol Management: Issues and Options ACPE#: 422-000-07-203-H01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	04/24/09	1.00	General CE
Generic Drugs: A Law CE ACPE#: 422-000-09-604-H03-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	05/02/09	1.00	Law CE
Emerging Developments in Drug Therapy and Implementation into Patient Care August 2007 ACPE#: 422-000-07-008-H01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	05/07/09	1.00	General CE
<i>PL CE LIVE</i> May Forum 2009 ACPE#: 422-000-09-505-L01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	05/19/09	1.00	Live CE
Emerging Developments in Drug Therapy and Implementation into Patient Care June 2009 ACPE#: 422-000-09-006-H01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	05/27/09	1.00	General CE
<i>PL CE LIVE</i> June Forum 2009 ACPE#: 422-000-09-506-L01-P Knowledge-based CE c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)	06/30/09	1.00	Live CE

PL CE LIVE July Forum 2009
ACPE#: 422-000-09-507-L01-P
Knowledge-based CE

07/14/09 1.00 Live CE

c19992e8-aff-46aa-9b95-e198ea186ec9 (printed previously)

and is awarded 24.00 total Contact Hours



A handwritten signature in black ink that reads 'Tony R. Martin'.

Tony R. Martin, Pharm.D., MBA October 25, 2010

These courses are sponsored by
Pharmacist's Letter, 3120 W. March Lane, PO Box 8190, Stockton, CA 95208
TEL: (209) 472-2240 FAX: (209) 472-2249

Print

Close Window